Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Adil Javed

TitleAssociate Professor
InstitutionUniversity of Chicago
DepartmentNeurology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Adil Javed, MD, PhD has expertise in autoimmune diseases of the brain and spine, including multiple sclerosis, lupus, Sjögren's disease, and other related connective tissue diseases. He has particular clinical and research interests in neuromyelitis optica (NMO), also known as Devic's disease. In addition, he specializes in nervous system complications of infectious and post-infectious diseases.

    Dr. Javed is also a principle investigator in several multiple sclerosis trials. His translational research interests include analyzing brain pathology using new and unconventional magnetic resonance imaging (MRI) techniques.


    Collapse Biography 
    Collapse education and training
    The University of Chicago Medicine, ILFellowship
    Yale University School of Medicine, CTResidency
    Evanston Northwestern Hospital, ILInternship
    Southern Illinois University, ILM.D.
    Southern Illinois University, ILPh.D.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Koskimäki F, Bernard J, Yong J, Arndt N, Carroll T, Lee SK, Reder AT, Javed A. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. PLoS One. 2018; 13(12):e0209326. PMID: 30576361.
      View in: PubMed
    2. Conte WL, Arndt N, Cipriani VP, Dellaria A, Javed A. Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol. Mult Scler Relat Disord. 2019 Jan; 27:397-399. PMID: 30508784.
      View in: PubMed
    3. Cipriani VP, Arndt N, Pytel P, Reder AT, Javed A. Effective treatment of CLIPPERS with long-term use of rituximab. Neurol Neuroimmunol Neuroinflamm. 2018 May; 5(3):e448. PMID: 29511706.
      View in: PubMed
    4. Daif A, Lukas RV, Issa NP, Javed A, VanHaerents S, Reder AT, Tao JX, Warnke P, Rose S, Towle VL, Wu S. Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy Behav. 2018 03; 80:331-336. PMID: 29433947.
      View in: PubMed
    5. Memon AB, Javed A, Caon C, Srivastawa S, Bao F, Bernitsas E, Chorostecki J, Tselis A, Seraji-Bozorgzad N, Khan O. Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS One. 2018; 13(1):e0190425. PMID: 29309416.
      View in: PubMed
    6. Bertsch-Gout M, Loeb R, Finch AK, Javed A, Bernard J. High resolution retinal scanning reveals regional structural differences between MS and NMOSD optic neuritis regardless of antibody status. J Neurol Sci. 2018 Jan 15; 384:61-66. PMID: 29249380.
      View in: PubMed
    7. Talmage GD, Coppes OJM, Javed A, Bernard J. Correction: Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study. PLoS One. 2017; 12(5):e0178338. PMID: 28542604.
      View in: PubMed
    8. Talmage GD, Coppes OJM, Javed A, Bernard J. Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study. PLoS One. 2017; 12(4):e0173299. PMID: 28426702.
      View in: PubMed
    9. Javed A, Reder AT. Rising JCV-Ab index during natalizumab therapy for MS: Inauspicious for a highly efficacious drug. Neurol Neuroimmunol Neuroinflamm. 2016 Feb; 3(1):e199. PMID: 26848488.
      View in: PubMed
    10. Khan O, Williams MJ, Amezcua L, Javed A, Larsen KE, Smrtka JM. Multiple sclerosis in US minority populations: Clinical practice insights. Neurol Clin Pract. 2015 Apr; 5(2):132-142. PMID: 26137421.
      View in: PubMed
    11. Javed A, Khan O. Acute disseminated encephalomyelitis. Handb Clin Neurol. 2014; 123:705-17. PMID: 25015513.
      View in: PubMed
    12. Fan Y, McGowan S, Rubeiz H, Wollmann R, Javed A, Mastrianni J. Acute encephalopathy as the initial manifestation of CADASIL. Neurol Clin Pract. 2012 Dec; 2(4):359-361. PMID: 23634379.
      View in: PubMed
    13. Ren Z, Wang Y, Duan T, Patel J, Liggett T, Loda E, Brahma S, Goswami R, Grouse C, Byrne R, Stefoski D, Javed A, Miller SD, Balabanov R. Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica. J Immunol. 2012 Nov 01; 189(9):4602-11. PMID: 23008451.
      View in: PubMed
    14. Romero RS, Gutierrez I, Wang E, Reder AT, Bhatti MT, Bernard JT, Javed A. Homonymous hemimacular thinning: a unique presentation of optic tract injury in neuromyelitis optica. J Neuroophthalmol. 2012 Jun; 32(2):150-3. PMID: 22580830.
      View in: PubMed
    15. Feng X, Reder NP, Yanamandala M, Hill A, Franek BS, Niewold TB, Reder AT, Javed A. Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci. 2012 Feb 15; 313(1-2):48-53. PMID: 22036215.
      View in: PubMed
    16. Mahmood NA, Silver K, Onel K, Ko M, Javed A. Efficacy and safety of rituximab in pediatric neuromyelitis optica. J Child Neurol. 2011 Feb; 26(2):244-7. PMID: 21183724.
      View in: PubMed
    17. Pula JH, Javed A. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy. Curr Opin Ophthalmol. 2009 Nov; 20(6):476-81. PMID: 19816177.
      View in: PubMed
    18. Javed A, Balabanov R, Arnason BG, Kelly TJ, Sweiss NJ, Pytel P, Walsh R, Blair EA, Stemer A, Lazzaro M, Reder AT. Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler. 2008 Jul; 14(6):809-14. PMID: 18573828.
      View in: PubMed
    19. Boster A, Edan G, Frohman E, Javed A, Stuve O, Tselis A, Weiner H, Weinstock-Guttman B, Khan O. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol. 2008 Feb; 7(2):173-83. PMID: 18207115.
      View in: PubMed
    20. Javed A, Reder AT. Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol Ther. 2006 Apr; 110(1):35-56. PMID: 16229894.
      View in: PubMed
    21. Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Gray TS. 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci. 2001 May 15; 21(10):3572-9. PMID: 11331386.
      View in: PubMed
    22. Javed A, Kamradt MC, Van de Kar LD, Gray TS. D-Fenfluramine induces serotonin-mediated Fos expression in corticotropin-releasing factor and oxytocin neurons of the hypothalamus, and serotonin-independent Fos expression in enkephalin and neurotensin neurons of the amygdala. Neuroscience. 1999 Mar; 90(3):851-8. PMID: 10218785.
      View in: PubMed
    23. Javed A, Van de Kar LD, Gray TS. The 5-HT1A and 5-HT2A/2C receptor antagonists WAY-100635 and ritanserin do not attenuate D-fenfluramine-induced fos expression in the brain. Brain Res. 1998 Apr 27; 791(1-2):67-74. PMID: 9593827.
      View in: PubMed
    24. Javed A, Van De Kar LD, Gray TS. p-Chlorophenylalanine and fluoxetine inhibit D-fenfluramine-induced Fos expression in the paraventricular nucleus, cingulate cortex and frontal cortex but not in other forebrain and brainstem regions. Brain Res. 1997 Nov 07; 774(1-2):94-105. PMID: 9452197.
      View in: PubMed
    Javed's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _